An alternative non-brain-penetrant CB1 antagonist, AM6545, was studied thereafter, demonstrating reduced food intake without malaise, improved glycemic control, improved dyslipidemia, and reversal of hepatic steatosis [38,39]. This evidence concerns the gene CNR1 and metabolic syndrome.